Showing 1 - 6 results of 6 for search 'Wulffraat N', query time: 0.02s
Refine Results
-
1
-
2
-
3
2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic J... by Ruperto N, Quartier P, Wulffraat N, Woo P, Loy A, Mouy R, Bader-Meunier B, Prakken B, Noseda E, Rordorf C
Published 2008Connect to this object online.
Book -
4
When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis by Prince FHM, Twilt M, Simon SCM, van Rossum MAJ, Armbrust W, Hoppenreijs EPAH, Kamphuis SSM, van Santen-Hoeufft M, Koopman-Keemink Y, Wulffraat N, ten Cate R, van Suijlekom-Smit LWA
Published 2008Connect to this object online.
Book -
5
The PRINTO provisional definition of remission in juvenile dermatomyositis by Kasapcopur O, Ganser G, Ferriani V, Penades I, Dolezalova P, Quartier P, Hofer M, Garay S, Wulffraat N, Pilkington C, Malattia C, Ravelli A, Miettunen P, Pistorio A, Lazarevic D, Melo-Gomes JA, Wierzbowska M, Martini A, Ruperto N
Published 2011Connect to this object online.
Book -
6
Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data by Espada G, Pardeo M, Chaitow J, Brown D, Allen R, Zulian F, Zuber Z, Wulffraat N, Joos R, Dolezalova P, Burgos-Vargas R, Woo P, Schneider R, Ruperto N, Brunner H, De Benedetti F, Flato B, Gerloni V, Horneff G, Wright S, Kenwright A, Lovell D, Martini A
Published 2011Connect to this object online.
Book